Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Weiguo, Zhang, Meng, Wu, Zhuo-Xun, Wang, Jing-Quan, Dong, Xing-Duo, Yang, Yuqi, Teng, Qiu-Xu, Chen, Xuan-Yu, Cui, Qingbin, Yang, Dong-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330633/
https://www.ncbi.nlm.nih.gov/pubmed/32670878
http://dx.doi.org/10.3389/fonc.2020.00955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330633/
https://www.ncbi.nlm.nih.gov/pubmed/32670878
http://dx.doi.org/10.3389/fonc.2020.00955

Ejemplares similares